Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Neomorph, Inc
Neomorph, Inc
Bristol-Myers Squibb
Xencor, Inc.
Nuvectis Pharma, Inc.
Arcus Biosciences, Inc.
Pfizer
Tizona Therapeutics, Inc
HiberCell, Inc.
Novartis
Kura Oncology, Inc.
Merck Sharp & Dohme LLC
AstraZeneca
Coherus Oncology, Inc.
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Genentech, Inc.
DEKA Biosciences
Five Eleven Pharma, Inc.
Molecure S.A.
Astellas Pharma Inc
Inhibrx Biosciences, Inc
Taiho Oncology, Inc.
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Celldex Therapeutics
AO GENERIUM
Aurigene Discovery Technologies Limited
Corvus Pharmaceuticals, Inc.
Lisata Therapeutics, Inc.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
AvenCell Therapeutics, Inc.
Janssen Research & Development, LLC
Bristol-Myers Squibb
Quadriga Biosciences, Inc.
Syndax Pharmaceuticals
Pfizer
Lumos Pharma
Pfizer
Novartis
Syndax Pharmaceuticals
Corvus Pharmaceuticals, Inc.
Novartis
NanOlogy, LLC
Celldex Therapeutics
Celgene
Cancer Targeted Technology
Celldex Therapeutics
Celldex Therapeutics
Santa Maria Biotherapeutics
Amgen
Valerio Therapeutics
Valerio Therapeutics